Find in Library

<p><strong>Objective:</strong> to reveal the features of chronic heart failure (CHF) of ischemic genesis concurrent with chronic obstructive pulmonary disease (COPD) and to investigate the effect of the cardioselective β1-adrenoblocker (β1-AB) nebivolol on the course of COPD and the parameters of the bronchopulmonary system in patients with CHF of ischemic genesis during treatment.</p><p><br /><strong>Subjects and methods.</strong>The investigation enrolled 63 patients aged 40–70 years, including 43 patients with functional class (FC) II–IV CHF with a Simpson left ventricular ejection fraction of  45 % concurrent with COPD (a study group) and 20 patients with CHF and no bronchopulmonary pathology (a control group). The study group patients were randomly divided into 2 subgroups: 1) 23 patients who received nebivolol in addition to background therapy; 2) 20 patients in whom the therapy ruled out the use of β1-AB. The control patients were switched to nebivolol therapy. During 6-month follow-up, the authors made clinical examination, recorded the rate, duration, and severity of COPD exacerbations, performed a 6-minute walking test (6MWT), and used a clinical status scale modified by R. Cody, a dyspnea 0–10 category ratio (Borg scale), and a Medical Research Council Dyspnoea Scale (MRS scale). Besides, quality of life in patients was assessed using the specific Minnesota Living with Heart Failure Questionnaire. All the patients underwent echocardiography, bronchodilatation-induced external respiratory function test, peak flowmetry, and blood brain natriuretic peptide quantification. These studies were conducted at baseline and at 1 and 6 months of therapy.</p><p><strong>Results.</strong> During the investigation, the patients with CHF concurrent with COPD were found to have a high rate of hypertensive disease, prior myocardial infarctions, atrial fibrillations, and higher FC exertional angina. These patients also showed a delayed optimal result achievement during the combination therapy involving the use of β1-AB. The group of patients without concomitant COPD was observed<br />to have lower FV CHF and significantly reduced dyspnea during exercise (Borg scale) immediately following 1-month therapy whereas these were seen only after 6 months. Nebivolol (mean dose 5 mg) included in the treatment regimen for patients with CHF concurrent with COPD failed to have a significant effect on spirometric and peak flowmetric readings, but had a clear-cut positive effect on the health indicators of CHF patients, such as FC of the disease, heart rate, 6MWT distance, degree of dyspnea degree, and quality of life.</p><p><br /><strong>Conclusion.</strong> Combination cardiopulmonary therapy including β1-AB leads to more effective control of comorbidity symptoms and to improvement<br />of patient functional status.</p>